Chronic kidney disease affects approximately 850 million people globally, with hyperkalemia representing a disproportionately high burden in this population¹. While hyperkalemia occurs in only 2-3% of ...
"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results